Skip to main content

Table 1 Unadjusted hazard ratios for death in relation to stromal ER and PR expression, allover and stratified by KRAS mutation status and sex, respectively

From: Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma

 

All

KRAS wild-type

KRAS mutated

 

n (events)

HR (95% CI)

n (events)

HR (95% CI)

n (events)

HR (95% CI)

Pinteraction

ER status

 All

  ER-

118 (93)

1.00

40 (27)

1.00

34 (28)

1.00

0.694

  ER+

48 (39)

0.97 (0.67–1.41)

13 (10)

1.14 (0.55–2.37)

12 (11)

0.93 (0.46–1.88)

0.757a

  p

 

0.865

 

0.721

 

0.841

 

 Women

  ER-

49 (35)

1.00

17 (10)

1.00

14 (10)

1.00

0.874

  ER+

35 (26)

1.05 (0.63–1.74)

8 (5)

1.09 (0.37–3.22)

8 (7)

1.35 (0.50–3.65)

0.947a

  p

 

0.864

 

0.870

 

0.548

 

 Men

  ER-

69 (58)

1.00

23 (17)

1.00

20 (18)

1.00

0.387

  ER+

13 (13)

1.12 (0.61–2.05)

5 (5)

1.30 (0.47–3.59)

4 (4)

0.63 (0.21–1.92)

0.516a

  p

 

0.723

 

0.613

 

0.420

 

PR status

 All

  PR-

111 (86)

1.00

38 (24)

1.00

29 (26)

1.00

0.026

  PR+

49 (43)

1.25 (0.87–1.81)

12 (11)

1.94 (0.94–3.98)

17 (14)

0.66 (0.34–1.27)

0.037a

  p

 

0.234

 

0.071

 

0.216

 

 Women

  PR-

52 (36)

1.00

18 (9)

1.00

12 (11)

1.00

0.002

  PR+

28 (24)

1.35 (0.80–2.27)

6 (6)

2.85 (1.01–8.09)

9 (6)

0.030 (0.11–0.85)

0.004a

  p

 

0.257

 

0.048

 

0.024b

 

 Men

  PR-

59 (50)

1.00

20 (15)

1.00

17 (15)

1.00

0.678

  PR+

21 (19)

1.23 (0.72–2.09)

6 (5)

1.32 (0.47–3.70)

8 (8)

1.70 (0.71–4.07)

0.785a

  p

 

0.452

 

0.592

 

0.234

 
  1. aInteraction analysis including adjustment for morphological type (I-type/PB-type)
  2. bHazard ratio adjusted for morphological type 0.28 (0.10–0.80) in women